---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-023216"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T20:23:47.510171+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cellectar Biosciences FY2024 net loss $44.6M; FDA agrees on accelerated approval path for iopofosine I 131

## Summary
- Net loss of $44.6M ($1.22 basic EPS) vs $42.8M in 2023; cash $23.3M as of Dec 31, 2024.
- FDA aligned on regulatory path for accelerated approval of iopofosine I 131 in WM; confirmatory study (100/arm) expected to cost $40M-$45M.
- Phase 2 CLOVER-WaM data: ORR 83.6%, MRR 58.2% (exceeded FDA 20% endpoint).
- G&A expenses surged to $25.6M from $11.7M due to commercialization infrastructure; R&D $26.1M slightly down.
- IND cleared for Auger-emitting radioconjugate; alpha-emitting IND planned H1 2025.

## SEC filing metadata
- accession: 0001104659-25-023216
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925023216/0001104659-25-023216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925023216/tm259072d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-023216
- JSON: https://secwatch.observer/filing/0001104659-25-023216.json
- Plain text: https://secwatch.observer/filing/0001104659-25-023216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.